NCT03719664 - Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2018

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

HIV-1-infection

Interventions

DRUG

Albuvirtide

Intravenous infusion of Albuvirtide

DRUG

3BNC117

Intravenous infusion of 3BNC117

DRUG

Baseline ART

Subjects continuing on baseline ART

Trial Locations (7)

RECRUITING

ABT-3BNC117_201 Investigational Site, New York

RECRUITING

ABT-3BNC117_201 Investigational Site, Atlanta

RECRUITING

ABT-3BNC117_201 Investigational Site, Orlando

RECRUITING

ABT-3BNC117_201 Investigational Site, Hialeah

RECRUITING

ABT-3BNC117_201 Investigational Site, Ft. Pierce

RECRUITING

ABT-3BNC117_201 Investigational Site, Palm Springs

RECRUITING

ABT-3BNC117_201 Investigational Site, San Francisco